Old Web
English
Sign In
Acemap
>
authorDetail
>
K De Beuf
K De Beuf
Ablynx
Medicine
Internal medicine
Interleukin-6 receptor
Diabetes mellitus
Physical therapy
3
Papers
80
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Caplacizumab reduces the frequency of major thromboembolic events, exacerbations, and death in patients with acquired thrombotic thrombocytopenic purpura.
2017
Journal of Thrombosis and Haemostasis
Flora Peyvandi
Marie Scully
J. A. Kremer Hovinga
Paul Knöbl
Spero R. Cataland
K De Beuf
Filip Callewaert
H. de Winter
Robert K. Zeldin
Show All
Source
Cite
Save
Citations (66)
FRI0239 Results of a phase 2b study of vobarilizumab, an anti-interleukin-6 receptor nanobody, as monotherapy in patients with moderate to severe rheumatoid arthritis
2017
Annals of the Rheumatic Diseases
Thomas Dörner
Michael E. Weinblatt
K. Van Beneden
Ej Dombrecht
K De Beuf
P. Schoen
Robert K. Zeldin
Show All
Source
Cite
Save
Citations (12)
OP0098 Remission and maintenance of efficacy in a phase 2b study of vobarilizumab, an anti-interleukin 6 receptor nanobody, in patients with moderate-to-severe rheumatoid arthritis despite treatment with methotrexate
2017
Annals of the Rheumatic Diseases
Thomas Dörner
Michael E. Weinblatt
Patrick Durez
Rieke Alten
K Van Beneden
Ej Dombrecht
K De Beuf
P. Schoen
Robert K. Zeldin
Show All
Source
Cite
Save
Citations (2)
1